查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138269

2022-2029 年全球皮肤癌市场

Global Skin Cancer Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

全球皮肤癌市场的增长是由皮肤癌发病率增加、全球变暖加剧导致臭氧消耗以及治疗意识的提高推动的，尤其是在新兴国家。

皮肤癌确诊人数不断增加，有望成为市场增长的驱动力。

1994 年至 2020 年间，美国非黑色素瘤皮肤癌的诊断和治疗增加了 77%。大约 90% 的非黑色素瘤皮肤癌与阳光暴露于紫外线 (UV) 辐射有关。根据美国皮肤病学会的数据，美国每天约有 9,500 人被诊断出患有皮肤癌。估计到 2021 年美国将诊断出 196,060 例新的黑色素瘤，其中包括 101,280 例原位黑色素瘤和 106,110 例侵袭性黑色素瘤。预计到 2021 年，侵袭性黑色素瘤将成为男性（62,260 例）和女性（43,850 例）中第五大最常诊断的癌症。非西班牙裔白人的皮肤癌发病率大约是非西班牙裔黑人和亚洲/太平洋岛民的 30 倍。皮肤白皙的人的皮肤癌通常在难以治疗的后期被诊断出来。

当癌症扩散到附近的淋巴结时，25% 的非裔美国人黑色素瘤患者被诊断出来。另一方面，当癌症扩散到远处的淋巴结或其他器官时，16% 的人被诊断出来。据说皮肤癌更容易发生在没有暴露在阳光下的部位，例如手掌、脚底、腹股沟和嘴巴周围。黑色素瘤也可以在指甲下形成。 50 岁之前女性的皮肤癌发病率高于男性，50 岁之后的男性发病率更高，这与娱乐和工作相关的紫外线照射的差异有关。似乎研究表明，在 15 至 39 岁之间被诊断出患有黑色素瘤的男性比同年龄段被诊断出患有黑色素瘤的女性死亡的可能性高 55%。因此，在预测期内，增加皮肤癌诊断将推动市场的增长。

皮肤癌诊断的高成本预计将阻碍市场增长。

平均 150,000 美元的癌症治疗费用是治疗其他常见疾病费用的四倍多。根据疾病控制和预防中心 (CDC) 的数据，治疗所有类型的皮肤癌估计每年至少花费 80 亿美元。该机构估计，到 2030 年，治疗新的黑色素瘤患者的费用将达到 16 亿美元。因此，这些因素将阻碍预测期内的市场增长。

行业分析

皮肤癌市场根据波特五力、未满足的需求、流行病学和供应链分析等各种行业因素对市场进行深入分析。

细分分析

在预测期间（2022-2029 年），非黑色素瘤部分预计将以最快的复合年增长率增长。

非黑色素瘤皮肤癌在早期通常被视为简单的病变，但如果治疗不当，会迅速扩散到身体的其他部位。目前，全世界每年约有 200 万例非黑色素瘤皮肤癌病例和约 132,000 例黑色素瘤皮肤癌病例发生。此外，根据美国临床肿瘤学会 (ASCO) 的估计，到 2022 年，美国每年将有 330 万人中的 540 万人被诊断出患有基底细胞癌和鳞状细胞癌。有些人被诊断出患有不止一种皮肤癌。几年来，除黑色素瘤以外的皮肤癌数量一直在增加。这可能是由于早期发现疾病、增加阳光照射和延长寿命。基底细胞癌比鳞状细胞癌更常见。除黑色素瘤外，大约 80% 的皮肤癌是基底细胞癌。因此，它是美国最常见的恶性肿瘤，具有相当大的相关发病率和成本以及相对较小但显着的死亡率。非黑色素瘤皮肤癌的治疗通常是成功的，因为与其他类型的癌症不同，癌症扩散到身体其他部位的风险显着降低。治疗黑色素瘤以外的皮肤癌在大约 90% 的病例中是成功的。因此，预计非黑色素瘤皮肤癌发病率和治疗后成功率的增加将推动预测期内的市场增长。

COVID-19 影响分析

COVID-19 大流行对医疗保健系统和皮肤癌市场产生了负面影响。根据发表在 Cancer Connect 2020 上的一篇文章，Dana-Farber Cancer Institute 的医生髮现，在 COVID-19 流行期间，包括皮肤癌在内的六种最常见癌症的诊断率下降了 46%。此外，美国疾病控制和预防中心 (CDC) 和许多医疗保健专业人员正在推迟健康预防服务，例如癌症筛查和择期手术，除非风险大于收益，并敦促人们治疗 COVID-19 患者. 他建议保护医院基础设施。因此，COVID-19 大流行正在影响皮肤癌市场。

全球皮肤癌市场报告提供对大约 45 多个市场数据表、40 多个图表和 180 页的访问。

内容

第 1 章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按适应症类型划分的市场细分
  • 按处理方法划分的市场细分
  • 按诊断划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 促进因素
      • 提高对皮肤癌治疗的认识
      • 皮肤癌诊断人数增加
    • 抑制因素
      • 皮肤癌诊断的高昂费用阻碍了市场增长。
    • 商机
    • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章适应症

  • 黑色素瘤
  • 非黑色素瘤
    • 基底细胞癌
    • 鳞状细胞癌
    • 默克尔细胞癌

第 8 章治疗

  • 化疗
  • 光动力疗法
  • 免疫疗法
  • 靶向治疗
  • 放射治疗
  • 其他治疗

第 9 章诊断

  • 皮肤镜检查
  • 皮肤活检
  • 淋巴结活检
  • 图像检查
  • 验血
  • 其他

第 10 章最终用户

  • 医院
  • 癌症研究所
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司

第 13 章公司简介

  • Amgen, Inc.
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Abbott Laboratories.
  • Sanofi SA
  • Novartis AG
  • Qiagen NV
  • Pfizer Inc.（*LIST NOT EXHAUSTIVE）

第 14 章数据M

简介目录
Product Code: DMPH319

Market Overview

Skin Cancer Market is expected to grow at a CAGR 8% during the forecasting period (2022-2029). Skin cancer is the most common type of cancer caused due to abnormal growth of skin cells. It is estimated that 90% of skin cancer is caused majorly due to solar and artificial ultraviolet radiation (UV). Ultraviolet radiation is a primary carcinogen that results in UV-induced mutations, loss of activity in tumor suppressor genes, and the overexpression of oncogenes in keratinocytes, thus boosting the development of skin malignancies.

The Skin Cancer Market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global market based on the Skin Cancer Market segmentation by treatment type, and end user. It also provides Skin Cancer Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global Skin Cancer Market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Market Dynamics

The global skin cancer market growth is driven by the growing incidents of skin cancer, rise in global warming leading to depletion of ozone layer and increasing awareness about the treatment especially in the emerging nations.

The growing diagnosis of skin cancer is expected to drive market growth.

The diagnosis and treatment of nonmelanoma skin cancers in the U.S. increased by 77 percent between 1994 and 2020. About 90 percent of nonmelanoma skin cancers are associated with sun exposure to ultraviolet (UV) radiation. The American Academy of Dermatology Association, approximately 9,500 people in the U.S. are diagnosed with skin cancer daily. It is estimated that 196,060 new cases of melanoma, 101,280 noninvasive (in situ), and 106,110 invasives will be diagnosed in the U.S. in 2021. Invasive melanoma is projected to be the fifth most commonly diagnosed cancer for men (62,260 cases) and women (43,850 cases) in 2021. The incidence of skin cancer among non-Hispanic white individuals is almost 30 times higher than that among non-Hispanic Black or Asian/Pacific Islander individuals. Skin cancer in patients with skin color is often diagnosed in its later stages when it's more difficult to treat.

Twenty-five percent of melanoma cases in African American patients are diagnosed when cancer has spread to nearby lymph nodes. In contrast, 16% are diagnosed when cancer has spread to distant lymph nodes and other organs. People with skin color are prone to skin cancer in areas that aren't commonly exposed to the sun, like the palms of the hands, the soles of the feet, the groin and the mouth. They also may develop melanoma under their nails. Skin cancer rates are higher in women than in men before age 50 but are higher in men after age 50, which may be related to differences in recreation and work-related UV exposure. Research indicates that males diagnosed with melanoma between the ages of 15 and 39 are 55% more likely to die than females diagnosed with melanoma in the same age group. Thus, the growing skin cancer diagnosis will drive the market's growth in the forecast period.

The high cost of skin cancer diagnosis is expected to hamper the market growth.

At an average of $150,000, cancer treatment costs are more than four times higher than treatment for other common health conditions. As per the Centers for Disease Control and Prevention (CDC), it is estimated that treatment for all kinds of skin cancer costs at least $8 billion per year. The agency projects that the annual cost of treating new patients with melanoma will be $1.6 billion by 2030. Thus these factors will hamper the market's growth in the forecast period.

Industry Analysis

The skin cancer market provides in-depth analysis of the market based on various industry factors such as porter five forces, unmet needs, epidemiology, supply chain analysis etc.

Segmentation Analysis

The Non-melanoma segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages, but if not treated properly, it can quickly spread to other body parts. Currently, around 2-3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally yearly. Moreover, according to the American Society of Clinical Oncology (ASCO), in 2022, it is estimated that 5.4 million cases of basal cell carcinoma and squamous cell carcinoma will be diagnosed annually in the United States among 3.3 million people. Some people are diagnosed with more than 1 skin cancer. The number of non-melanoma skin cancers has been growing for several years. This is likely due to earlier detection of the disease, increased sun exposure, and longer life spans. Basal cell carcinoma is far more common than squamous cell carcinoma. About 80% of non-melanoma skin cancers are basal cell carcinoma. Thus, it is the most common malignancy in the United States, with substantial associated morbidity and cost and relatively small but significant mortality. Treatment for non-melanoma skin cancer is usually successful, as unlike the other types of cancer, there's a significantly lower risk of cancer spreading to other parts of the body. Treatment for non-melanoma skin cancer is successful in approximately 90% of cases. Hence, the increasing rates of non-melanoma skin cancer and its success rates after treatment will drive the market's growth in the forecast period.

Geographical Analysis

North American region holds the largest market share of the global skin cancer market.

In 2021, the North American region accounted for the largest market share. As per the American Academy of Dermatology, skin cancer is the most common cancer in the United States. Most cases of melanoma, the deadliest kind of skin cancer, are caused by exposure to ultraviolet (UV) light. It is estimated that approximately 9,500 people in the United States are diagnosed with skin cancer every day. Furthermore, according to the latest SEER data, melanoma is the fifth most common cancer diagnosis in the US (excluding non-melanoma skin cancers), with 106,000 estimated new cases in 2021, representing 5.6% of all cancer diagnoses. Thus, the increasing incidences of skin cancer in the region are a major factor driving the market growth.

Additionally, the recent advancements in skin cancer therapy, including photodynamic therapy (PDT), have been widely used in treating non-melanoma skin malignancies, thus driving the growth of the skin cancer market during the forecast period. For instance, Nanotechnology-based therapy is gaining popularity and becoming an essential topic to debate. Skin cancer nanotherapy is approached in a variety of ways and tactics. Nanoparticles targeting carcinoma cells, functionalized nanoparticles for specific targeting to cancer cells, receptor-mediated active targeting as nanoshells, nanostructured lipid carriers, liposome, ethosome, bilosome, polymeric nanoparticle, nanosphere, dendrimers, carbon nanotubes, quantum dots, solid lipid nanoparticles, and fullerenes that are highly efficient in the specific killing of cancer cells are all examples of strategic approaches.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems and the skin cancer market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types, including skin cancer. Moreover, the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweigh the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the skin cancer market.

Competitive Landscape

Major key players in the skin cancer market are Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Abbott Laboratories., Sanofi SA, Novartis AG, Qiagen NV and Pfizer Inc. among others.

Amgen:

Overview:

Amgen is one of the world's leading biotechnology companies. It is engaged in pharmaceutical product research, development, and manufacturing. Amgen is a values-based company deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. The company offers a wide range of products for treating the central nervous system, neurosciences, ophthalmology, cancer, medical aesthetics, plastic surgery, dermatology, liver disease, inflammation, metabolic syndromes, and fibrosis. Amgen has 40 manufacturing facilities and 27 R&D, and Amgen, Inc is a biotechnology company that engages in the discovery, development, manufacture and marketing of human therapeutics and marketing facilities across the world.

­Product Portfolio:

IMLYGIC: IMLYGIC (talimogene laherparepvec) is a prescription medication used to treat a type of skin cancer called melanoma when it is on your skin or in your lymph glands.

The global skin cancer market report would provide an access to an approx. 45+market data table, 40+figures and 180pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Indication Type
  • 3.2. Market snippet By Treatment
  • 3.3. Market snippet By Diagnosis
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing awareness about the treatment of skin cancer
      • 4.1.1.2. The growing diagnosis of skin cancer
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of skin cancer diagnosis will hamper the market growth
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Indication Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type Segment
    • 7.1.2. Market Attractiveness Index, By Indication Type Segment
  • 7.2. Melanoma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Non-melanoma
    • 7.3.1. Basal cell carcinoma
    • 7.3.2. Squamous cell carcinoma.
    • 7.3.3. Merkel cell cancer

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Chemotherapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Photodynamic Therapy
  • 8.4. Immunotherapy
  • 8.5. Targeted Therapy
  • 8.6. Radiation Therapy
  • 8.7. Other Treatments

9. By Diagnosis

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 9.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 9.2. Dermatoscopy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Skin Biopsy
  • 9.4. Lymph Node Biopsy
  • 9.5. Imaging Tests
  • 9.6. Blood Tests
  • 9.7. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospital*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Cancer Research Institutes
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2019-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. Key Companies to Watch

13. Company Profiles

  • 13.1. Amgen, Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Bristol-Myers Squibb Company
  • 13.3. F. Hoffmann-La Roche Ltd
  • 13.4. Merck & Co., Inc.
  • 13.5. Sun Pharmaceutical Industries Ltd.
  • 13.6. Abbott Laboratories.
  • 13.7. Sanofi SA
  • 13.8. Novartis AG
  • 13.9. Qiagen NV
  • 13.10. Pfizer Inc.(*LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us